Bristol Myers Squibb CompanyBMY announced encouraging 18 month survival data from the phase III CheckMate 057 study on the intravenous anti PD1 immune checkpoint inhibitor, Opdivo. The open label, randomized phase III study, CheckMate 057, compared the use of